Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - CNS tumours

5380 - Results of Phase 2 Trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)


19 Oct 2018


Proffered Paper session - CNS tumours


Clinical Research;  Immunotherapy

Tumour Site

Central Nervous System Malignancies


David Peereboom


Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273


D. Peereboom1, L..B. Nabors2, P. Kumthekar3, M. Badruddoja4, K. Fink5, F. Lieberman6, S. Phuphanich7, E. Dunbar8, T. Walbert9, D. Schiff10, D.D. Tran11, L.S. Ashby12, N. Butowski13, F. Iwamoto14, R. Lindsay15, J. Bullington16, M. Schulder17, J. Sherman18, C. Brooks15, D. Reardon19

Author affiliations

  • 1 Brain Tumor And Neuro-oncology Center, Cleveland Clinic Foundation, 44195 - Cleveland/US
  • 2 Neuro-oncology, University of Alabama Comprehensive Cancer Center, Birmingham/US
  • 3 Department Of Neurology And Department Of Medicine, The Ken &Roth Davee, Chicago/US
  • 4 Neuro-oncology, Center for Neurosciences, Tucson/US
  • 5 Neuro-oncology, Baylor Scott&White Neuro-Oncology Associates, Dallas/US
  • 6 Division Of Hematology/oncology, University of Pittsburgh, Pittsburgh/US
  • 7 Department Of Neurology, Barrow Neurological Institute, Phoenix/US
  • 8 Piedmont Brain Tumor Center, Piedmont Helathcare, Atlanta/US
  • 9 Neuro-oncology, Henry Ford Health System, Detroit/US
  • 10 Neurology, University of Virginia School of Medicine, Charlottesville/US
  • 11 Department Of Neurosurgery, University of Florida, Gainesville/US
  • 12 Neuro-oncology, St. Joseph's Hospital and Medical Center, Phoenix/US
  • 13 Neurological Surgery, UCSF, San Francisco/US
  • 14 Neuro-oncology, Columbia University Medical Center, New York/US
  • 15 R&d, Stemline Therapeutics, 10022 - New York/US
  • 16 Clinical, Stemline Therapeutics, 10022 - New York/US
  • 17 Neuo-oncology, North Shore University Hospital, Manhasset/US
  • 18 Neurosurgery, George Washington University, Washignton DC/US
  • 19 Center For Neuro-oncology, Dana-Farber Cancer Institute, 2215 - Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5380


SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against targets overexpressed in glioblastoma (GBM): interleukin-13 receptor alpha-2, ephrinA2 and survivin. Updated phase 2 data are reported.


Patients enrolled had recurrent GBM, were HLA-A2+ and bevacizumab (bev)-naïve, and had KPS>60. In Stage 1, SL-701 was administered with adjuvants GM-CSF and imiquimod biweekly for 6 months, then q28 days. In Stage 2, SL-701 and adjuvant poly-ICLC were administered biweekly with bev (10 mg/kg) for 6 months, then q28 days. Primary objectives included safety, tolerability, investigator-assessed objective response rate (ORR) using RANO criteria, and 12-month overall survival rate (OS-12). SL-701-specific CD8+ T cells in PBMCs isolated from patients were assessed by flow cytometry using antibodies to CD3, CD4, CD8, IFNg, TNFa, IL-2, and PD-1.


Accrual for Stages 1 and 2 is complete. 74 patients [46 in Stage 1 and 28 in Stage 2; 65% male, median age of 57 years [(range: 24-79)] received SL-701. Five patients received SL-701 on compassionate use basis. The most frequent treatment-related adverse events (TRAEs) were fatigue (22%) and injection site reaction (18%). The most frequent grade 3-4 treatment-related adverse event was fatigue (n = 2; 2.7%). In Stage 1, a 22% disease control rate (DCR; CR+PR+SD for > =8 weeks) was observed, comprised of 1 PR (duration: 78 weeks) and 9 SD [median duration: 25 weeks (range: 3.7–120.9)] were observed. In Stage 2, a 54% DCR was observed consisting of 2 CRs (duration: 22 and 46 weeks), 2 PRs (duration: 38 and 54 weeks), and 11 SDs [median duration: 13.6 weeks (range: 1.6 – 35.1)] were observed. OS-12 was 44% in Stage 1 [95% CI 28.9, 58.9] and 50% [95% CI 30.6, 69.4] in Stage 2, and median OS was 11 months in Stage 1 and 11.7 months in Stage 2. Flow cytometry analysis of Stage 2 patients demonstrated CD8+ T cell responses to the SL-701 peptides.


SL-701 plus adjuvants with or without bevacizumab was well-tolerated and demonstrated anti-tumor activity, including multiple major responses and a preliminarily promising survival curve, warranting further study. Updated study data will be presented.

Clinical trial identification


Legal entity responsible for the study

Stemline Therapeutics.


Stemline Therapeutics.

Editorial Acknowledgement


R. Lindsay, J. Bullington, C. Brooks: Employment and stock ownership: Stemline Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.